# Shengxiang Ren

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/shengxiang-ren/

## Facts

| Field | Value |
| --- | --- |
| Citations | 17,103 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 60 |
| i10-index | 191 |
| Last Known Institution | Tongji University |
| OpenAlex ID | https://openalex.org/A5016049048 |
| ORCID iD | https://orcid.org/0000-0001-8767-9850 |
| Works | 366 |

## Researcher papers

- [Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study](https://scholariq.org/papers/erlotinib-versus-chemotherapy-as-first-line-treatment-for-patients-with-advanced/)
- [Role of IL-2 in cancer immunotherapy](https://scholariq.org/papers/role-of-il-2-in-cancer-immunotherapy/)
- [Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)](https://scholariq.org/papers/final-overall-survival-results-from-a-randomised-phase-iii-study-of-erlotinib/)
- [Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer](https://scholariq.org/papers/low-dose-apatinib-optimizes-tumor-microenvironment-and-potentiates-antitumor/)
- [Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial](https://scholariq.org/papers/camrelizumab-plus-carboplatin-and-paclitaxel-as-first-line-treatment-for/)
- [Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial](https://scholariq.org/papers/gefitinib-versus-vinorelbine-plus-cisplatin-as-adjuvant-treatment-for-stage-ii-2/)
- [Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG–0803)](https://scholariq.org/papers/erlotinib-as-second-line-treatment-in-patients-with-advanced-non-small-cell-lung/)
- [HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib](https://scholariq.org/papers/her2-exon-20-insertions-in-non-small-cell-lung-cancer-are-sensitive-to-the/)
- [Early detection of lung cancer by using an autoantibody panel in Chinese population](https://scholariq.org/papers/early-detection-of-lung-cancer-by-using-an-autoantibody-panel-in-chinese/)
- [Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?](https://scholariq.org/papers/immune-checkpoint-inhibitors-in-egfr-mutated-nsclc-dusk-or-dawn/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Tongji University](https://scholariq.org/institutions/tongji-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.